DE1617733A1 - Process for the production of a preparation for the treatment of wounds and suppurations that are difficult to heal - Google Patents
Process for the production of a preparation for the treatment of wounds and suppurations that are difficult to healInfo
- Publication number
- DE1617733A1 DE1617733A1 DE19671617733 DE1617733A DE1617733A1 DE 1617733 A1 DE1617733 A1 DE 1617733A1 DE 19671617733 DE19671617733 DE 19671617733 DE 1617733 A DE1617733 A DE 1617733A DE 1617733 A1 DE1617733 A1 DE 1617733A1
- Authority
- DE
- Germany
- Prior art keywords
- suppurations
- wounds
- parts
- heal
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Verfahren zur Herstellung eines Präparates für die Behandlung schwer heilender Wunden und Eiterungen0 Die Erfindung betrifft ein Verfahren zur Herstellung-- eines Arzneimittels für die Behandlung insbesondere von ohronischen, schwer heilenden Wunden, Geschwüren und Eiterungen und beruht auf der Erkenntnis, daß, wie anhand von Untersuchungen an Wundsekret von Patienten mit chronischen Infektionen erstmals nachgewiesen werden konnte, diese Sekrete proteolytische Enzyme vom Typ des Fibrinolysins (= Plasmin) enthalten, die Fibrin auflösen und damit den Heilungsvorgang behindern. Weil die Wundheilung mit der Bildung von Fibrin beginnt welches als Träger für heranwachsende Blutgefäße und Zellen dient, kann eine örtlich auftretende Fibrinolyse unter pathologischen zuständen die Bildung dieses Fibrins verhindern, Als Fibrinolyse wird die enzymatische Auflösung von Fibrin oder. dessen Vorstufe Fibrinogen bezeiohnat.Method of making a preparation for treating difficult healing wounds and suppurations 0 The invention relates to a method for the production of of a medicament for the treatment of particularly auricular, hard-to-heal Wounds, ulcers and suppurations and is based on the knowledge that how based of examinations on wound secretions from patients with chronic infections for the first time it could be demonstrated that these secretions are proteolytic enzymes of the fibrinolysin type (= Plasmin) that dissolve fibrin and thus hinder the healing process. Because wound healing begins with the formation of fibrin which acts as a carrier for adolescents Serving blood vessels and cells, localized fibrinolysis can be pathological conditions prevent the formation of this fibrin, as fibrinolysis is the enzymatic Dissolution of fibrin or. whose precursor fibrinogen bezeiohnat.
Aufgabe der Erfindung ist es, ein Verfahren zur Erstellung eines Arzneimittels zu entwickeln, welches bei seiner An wendung eine sclche örtliche Fibrinolyse möglichst gezielt durch örtliche Maßnahmen behebt oder verhindert. Dies wird erfindungsgemäß dadurch erreicht, daß geeignete Inhibitoren, wie z.B. #-Aminocapronsäure, Aminomethyl-benzoe-säure, trans-Aminomethylcyclohexanbenzoesäure od.dgl. gemeinsam mit einem die Freisetzung von Fibrinolyse-Aktivatoren verhinderndem Stoff, wia z. B. Natrium-Kupfer-Chlorophyllin einer Puder- oder Salbengrundlage zugesetzt werden.The object of the invention is to provide a method for producing a medicament to develop which local fibrinolysis if possible remedied or prevented in a targeted manner through local measures. This is according to the invention achieved by using suitable inhibitors, such as # -aminocaproic acid, aminomethyl-benzoic acid, trans-aminomethylcyclohexanebenzoic acid or the like. together with one the release of fibrinolysis activators preventing substance, wia z. B. Sodium-Copper-Chlorophyllin be added to a powder or ointment base.
Di. FiBrinolyse wird unter den beschriebenen bedingungen durch zugrundegehende gesohädigte Gewebezellen und weiße Blutkörperchen verursachte wobei eine Sogenannte Fibrinolysokinase freigesetzt wird, die das Proenzym Profibrinolysin (Plasminogen) des Wundsekrets in Fibrinolysin umwandelt.Di. FiBrinolyse is under the conditions described by underlying So-called damaged tissue cells and white blood cells caused what is called Fibrinolysokinase is released, which contains the proenzyme profibrinolysin (plasminogen) of the wound secretion is converted into fibrinolysin.
Das nach dem erfindungagemä#en Verfahren erstellte Arzneimittel zielt daher darauf ab, das Zugrundegehen der geschädigten Zellen soweit wie möglich zu verhindern oder zu verzögern und den Aktivierungsvorgang von Profibrinolysin zu Pibrinolysin örtlich zu inhibieren.The drug produced by the method according to the invention is aimed therefore aim to undergo the destruction of the damaged cells as much as possible prevent or delay and increase the activation process of profibrinolysin To locally inhibit pibrinolysin.
Diese beiden therapeutischen Wirkungen sind vorzugsweise nur in einem neutralen pH-Bereich von pH 7 zu erreichen. Es mu#te daher ein Inhibitorsystem gefunden werden, durch welches in diesem pH-Bereich sowohl der Zellzerfall wie auch die Aktivierung des Profibrinolysins beeinflu#t werden können.These two therapeutic effects are preferably only in one to reach a neutral pH range of pH 7. An inhibitor system therefore had to be found by which both cell disintegration and activation in this pH range of profibrinolysin can be influenced.
Als Inhibitor für die wirksame Hemmung des Zerfalls von geschädigten Zellen wi:ire a.i. .:iLue.r.4hlob';yj:li'n .se£.ndunm: erini-'t-et Als Indikator der Wirkung dient dabei die Freisetzung von Plasmin.As an inhibitor for the effective inhibition of the disintegration of damaged Cells wi: ire a.i. .: iLue.r.4hlob '; yj: li'n .se £ .ndunm: erini-'t-et as an indicator the effect is the release of plasmin.
Die Aktivierung von Fibrinolysin wird wirksam durch #-Aminocapronsäure, Aminomethyl-benzoesäure und trans-Aminomethylcyclohexanbenzoesäure unterbunden. Die Erkenntnis der Existenz einer lokalen Fibrinolyse ist völlig neu. eßhb ar .c ?-e- :3 5e?l' :kt., e --e örtliche Umwandlung von Profinbrinolysin in Fibrinolysin zweckmä#ig zu verhindern ist. Die beiden genannten Inhibitoren wurden als optimal wirksam ermittelt. Die Anwendung dieser Substanzen gemeinsam mit dem oben genannten Natrium-Kupfer-Chlorophyllin erwies sich als besc&ere reckmaßl-, il .eide n- hi-)r.en g1eic ; e1n .<ir die optimale Wirkung von Natrium-Kupfer-Chlorophyllin notwendigen pH 7,0 wirksam sind.The activation of fibrinolysin is effective by # -aminocaproic acid, Aminomethyl-benzoic acid and trans-aminomethylcyclohexanebenzoic acid prevented. The knowledge of the existence of local fibrinolysis is completely new. edible ar .c ? -e-: 3 5e? l ': kt., e --e local conversion of profinbrinolysin into fibrinolysin is expedient to prevent. The two inhibitors mentioned were found to be optimal effectively determined. The use of these substances together with the above Sodium-copper-chlorophyllin proved to be the better hi-) r.en g1eic; e1n. <ir the optimal effect of sodium-copper-chlorophyllin necessary pH 7.0 are effective.
Im folgenden ist ein für die Herstellung von Puder und Salbe zweckmä#iges Rezept zusammengestellt Beispie le 1. #-Aminocapronsäure Natrium-Kupfer-Chlorophyllin 0,2 Milchzucker ad 100,0 (Pudergrundla 2. #-Aminocapronsäure 2,0 Natrium-Kupfer-Chlorophyllin 0,2 (Salbengrundlage) Eucerini c. aqua ad 100,0 Mit diesen Zubereitungen konnte übereinstimmend eine überraschend schnell le Abheilung auch von chronischen, bereits lange Zeit bestehenden Unterschenkelgeschwüren usw. erreicht werden.The following is a useful one for the production of powder and ointment Recipe compiled examples 1. # -aminocaproic acid sodium-copper-chlorophyllin 0.2 lactose ad 100.0 (powder base 2. # -aminocaproic acid 2.0 sodium-copper-chlorophyllin 0.2 (ointment base) Eucerini c. aqua ad 100.0 With these preparations was consistent with a surprisingly quick healing of chronic, leg ulcers, etc. that have existed for a long time can be achieved.
Ergänzend sei bemerkt, daß auch. die Erreger der eitrigen Infekte einen Aktivator absondern, der ebenfalls die. Aktivierung. zu Fibrinolysin bewirkt. Durch die gleichzeitige Gabe eines Lokalantibiotikums wird dieser Vorgang weitgehend unterbunden0In addition, it should be noted that also. the causative agents of purulent infections secrete an activator that also has the. Activation. causes fibrinolysin. This process is largely enhanced by the simultaneous administration of a local antibiotic prevented0
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP0041764 | 1967-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1617733A1 true DE1617733A1 (en) | 1971-04-08 |
Family
ID=7378066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19671617733 Pending DE1617733A1 (en) | 1967-03-31 | 1967-03-31 | Process for the production of a preparation for the treatment of wounds and suppurations that are difficult to heal |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1617733A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096345A2 (en) | 2005-03-04 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Coagulation and fibrinolytic cascades modulator |
US8821861B2 (en) | 2007-10-05 | 2014-09-02 | The Board Of Trustees Of The University Of Illinois | Fibrin sealant |
US9241958B2 (en) | 2007-11-09 | 2016-01-26 | The Board Of Trustees Of The University Of Illinois | Anticoagulant antagonist and hemophilia procoagulant |
-
1967
- 1967-03-31 DE DE19671617733 patent/DE1617733A1/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096345A2 (en) | 2005-03-04 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Coagulation and fibrinolytic cascades modulator |
WO2006096345A3 (en) * | 2005-03-04 | 2006-11-30 | Univ Illinois | Coagulation and fibrinolytic cascades modulator |
US7682808B2 (en) | 2005-03-04 | 2010-03-23 | The Board Of Trustees Of The University Of Illinois | Coagulation and fibrinolytic cascades modulator |
US9597375B2 (en) | 2005-03-04 | 2017-03-21 | The Board Of Trustees Of The University Of Illinios | Coagulation and fibrinolytic cascades modulator |
US8821861B2 (en) | 2007-10-05 | 2014-09-02 | The Board Of Trustees Of The University Of Illinois | Fibrin sealant |
US9241958B2 (en) | 2007-11-09 | 2016-01-26 | The Board Of Trustees Of The University Of Illinois | Anticoagulant antagonist and hemophilia procoagulant |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69433226T2 (en) | INTRAVASCULAR MEDICAL DEVICE | |
DE69030476T2 (en) | Use of protease inhibitors as anti-exudative, anti-inflammatory and anti-microbial agents | |
DE4411143C2 (en) | Thrombotic agents | |
DE2626109A1 (en) | INTESTINAL, DIGESTIVE ENZYME PREPARATIONS AND METHOD OF MANUFACTURING THEREOF | |
DE19851334A1 (en) | Flexible fibrin-based wound dressing and process for its manufacture | |
DE4420735C2 (en) | Process for the production of mechanically stable, high-speed effervescent tablets | |
EP1183043B1 (en) | Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors | |
DE3715662A1 (en) | NEW PHARMACEUTICAL APPLICATION | |
EP0008052B1 (en) | Anti-inflammatory and blood-stanching medicament | |
EP0328957B1 (en) | Mixture of a thrombolytically acting and an antithrombolytically acting substance | |
DE1617733A1 (en) | Process for the production of a preparation for the treatment of wounds and suppurations that are difficult to heal | |
EP0743070A2 (en) | Use of protease proenzymes and amylases as active agents in pharmaceutical compositions for cancer therapy and their preparation | |
EP0421023B1 (en) | Catabolic enzymes for the induction of the tumour necrosis factor (TNF) | |
DE102006038252A1 (en) | Preparation with marine collagen for proteinase inhibition | |
DE60034694T2 (en) | USE OF ELASTASE TO OPEN UNDERSTANDED ARTERIES AND VENES | |
Birn | Antifibrinolytic effect of Apernyl® in “dry socket” | |
RU2063237C1 (en) | Wound-healing agent | |
EP0603112A1 (en) | Use of thrombin inhibitors for inhibiting ocular fibrin formation | |
DE69930419T2 (en) | USE OF HUMAN PROTEIN C FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEPARINE-INDUCED THROMBOCYTOPENIA | |
Deutsch et al. | Fibrinolyse als Ursache einer Blutung bei Prostataresektion | |
EP0611571A1 (en) | Teicoplanin containing topical compositions with delayed release of the active agent | |
EP0189485A1 (en) | Hexapeptide | |
Graeff et al. | Blutung, Schock und Sepsis | |
Schenk et al. | Experimentelle Untersuchungen zur Frage der Resorption von Blut in der Vorderkammer durch Trypsin | |
DE903738C (en) | Process for the production of durable, therapeutically effective enzyme preparations |